ReviewFrontiers in pharmacology2013
Mind and body: how the health of the body impacts on neuropsychiatry.
Review in Frontiers in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP).Journal of neurology · 2021Pooled it
- Is There Any Association Between Chronic Periodontitis and Anxiety in Adults? A Systematic Review.Frontiers in psychiatry · 2021Pooled it
- High Cardiorespiratory Fitness Is Negatively Associated with Daily Cortisol Output in Healthy Aging Men.PloS one · 2015Trial
- Corticosteroid-Induced neuropsychiatric manifestations: From pathophysiology to management.Psychopharmacology · 2026Review
- Peripheral gene dysregulation in Negr1-deficient mice: insights into possible links with affective behavior.Frontiers in molecular neuroscience · 2025Article
- Chronic inflammatory demyelinating polyneuropathy. A case description.Clinical case reports · 2024Article
- Study protocol: combined N-of-1 trials to assess open-label placebo treatment for antidepressant discontinuation symptoms [FAB-study].BMC psychiatry · 2023Article
- The Metabolic Matrix: Re-engineering ultraprocessed foods to feed the gut, protect the liver, and support the brain.Frontiers in nutrition · 2023Article
- Physical activity, physical frailty and depressive symptoms among Chinese male and female older adults: do different indicators make a difference?Frontiers in public health · 2023Article
- Gut Microbiota Metabolites in Major Depressive Disorder-Deep Insights into Their Pathophysiological Role and Potential Translational Applications.Metabolites · 2022Review
- Spotlight on the Challenges of Depression following Retirement and Opportunities for Interventions.Clinical interventions in aging · 2022Review
- Physical Comorbidity According to Diagnoses and Sex among Psychiatric Inpatients in South Korea.International journal of environmental research and public health · 2021Article
- Analysis of Chronic Mild Stress-Induced Hypothalamic Proteome: Identification of Protein Dysregulations Associated With Vulnerability and Resiliency to Depression or Anxiety.Frontiers in molecular neuroscience · 2021Article
- Osteopathy and Mental Health: An Embodied, Predictive, and Interoceptive Framework.Frontiers in psychology · 2021Article
- Metabolomic Biomarkers in Anxiety Disorders.International journal of molecular sciences · 2020Review
- Metabolomics in Psychiatric Disorders: What We Learn from Animal Models.Metabolites · 2020Review
- Immune-mediated neuropathies.Nature reviews. Disease primers · 2018Review
- Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence.Frontiers in psychiatry · 2018Review
- Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy.Journal of neurology · 2017Article
- miR-34b attenuates trauma-induced anxiety-like behavior by targeting CRHR1.International journal of molecular medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has long been established in traditional forms of medicine and in anecdotal knowledge that the health of the body and the mind are inextricably linked. Strong and continually developing evidence now suggests a link between disorders which involve Hypothalamic-Pituitary-Adrenal axis (HPA) dysregulation and the risk of developing psychiatric disease. For instance, adverse or excessive responses to stressful experiences are built into the diagnostic criteria for several psychiatric disorders, including depression and anxiety disorders. Interestingly, peripheral disorders such as metabolic disorders and cardiovascular diseases are also associated with HPA changes. Furthermore, many other systemic disorders associated with a higher incidence of psychiatric disease involve a significant inflammatory component. In fact, inflammatory and endocrine pathways seem to interact in both the periphery and the central nervous system (CNS) to potentiate states of psychiatric dysfunction. This review synthesizes clinical and animal data looking at interactions between peripheral and central factors, developing an understanding at the molecular and cellular level of how processes in the entire body can impact on mental state and psychiatric health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.